Biofrontera Inc.

Biofrontera Inc. company information, Employees & Contact Information

Explore related pages

Biofrontera Inc. email format Biofrontera Inc. management contacts

Related company profiles:

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of dermatological drugs specializing on the fields of photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products focus on the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.

Company Details

Employees
70
Founded
-
Address
120 Presidential Way,
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
http://www.biofrontera-us.com
Keywords
jobs.
HQ
Woburn, Massachusetts
Competitors
Vertex Pharmaceuticals, Botanix Pharmaceuticals, Biofrontera Group, Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), Galderma, Dermavant Sciences, an Organon company, Incyte, AbbVie, Verrica Pharmaceuticals, Almirall.
Looking for a particular Biofrontera Inc. employee's phone or email?

Biofrontera Inc. Questions

News

Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG - GlobeNewswire

Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG GlobeNewswire

Biofrontera (NASDAQ: BFRI) acquires U.S. Ameluz and RhodoLED rights, $11M funding - Stock Titan

Biofrontera (NASDAQ: BFRI) acquires U.S. Ameluz and RhodoLED rights, $11M funding Stock Titan

Biofrontera Cuts Ameluz Royalties From 35% to 12%, Gains Full US Control with $11M Backing - Stock Titan

Biofrontera Cuts Ameluz Royalties From 35% to 12%, Gains Full US Control with $11M Backing Stock Titan

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - GlobeNewswire

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 GlobeNewswire

Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment - Yahoo Finance

Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment Yahoo Finance

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update - GlobeNewswire

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update GlobeNewswire

$11M Funded Dermatology Leader Biofrontera Taps Top IR Firm Following Major Business Transformation - Stock Titan

$11M Funded Dermatology Leader Biofrontera Taps Top IR Firm Following Major Business Transformation Stock Titan

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025 - GlobeNewswire

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025 GlobeNewswire

Dermatology Leader Biofrontera Announces Key Investor Conference Presentation at Lytham Fall 2025 - Stock Titan

Dermatology Leader Biofrontera Announces Key Investor Conference Presentation at Lytham Fall 2025 Stock Titan

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer - GlobeNewswire

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer GlobeNewswire

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update - GlobeNewswire

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update GlobeNewswire

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - GlobeNewswire

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market GlobeNewswire

Biofrontera Inc. Engages Lytham Partners to Lead Strategic - GlobeNewswire

Biofrontera Inc. Engages Lytham Partners to Lead Strategic GlobeNewswire

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris - GlobeNewswire

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris GlobeNewswire

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk - GlobeNewswire

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk GlobeNewswire

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris - GlobeNewswire

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris GlobeNewswire

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book - GlobeNewswire

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book GlobeNewswire

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s - GlobeNewswire

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s GlobeNewswire

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp - Yahoo Finance

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp Yahoo Finance

Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use - Yahoo Finance

Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use Yahoo Finance

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis - GlobeNewswire

Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis GlobeNewswire

Phase 3 Study of Ameluz-PDT in Superficial Basal Cell Carcinoma Reaches 1-Year Follow-Up to Support FDA sNDA Submission - OncLive

Phase 3 Study of Ameluz-PDT in Superficial Basal Cell Carcinoma Reaches 1-Year Follow-Up to Support FDA sNDA Submission OncLive

Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January - GlobeNewswire

Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January GlobeNewswire

Biofrontera Inc. Announces New Secured Line of Credit up to $6.5 Million - FinancialContent

Biofrontera Inc. Announces New Secured Line of Credit up to $6.5 Million FinancialContent

Biofrontera Names Fred Leffler as Chief Financial Officer - citybiz

Biofrontera Names Fred Leffler as Chief Financial Officer citybiz

Biofrontera Inc. Announces Pricing of $18.0 Million Initial Public Offering - GlobeNewswire

Biofrontera Inc. Announces Pricing of $18.0 Million Initial Public Offering GlobeNewswire

Companies like Biofrontera Inc.

Vertex Pharmaceuticals logo - Similar company to Biofrontera Inc.

Vertex Pharmaceuticals

6.09K
Verrica Pharmaceuticals logo - Similar company to Biofrontera Inc.

Verrica Pharmaceuticals

82
Dermavant Sciences, an Organon company logo - Similar company to Biofrontera Inc.

Dermavant Sciences, ...

208
Incyte logo - Similar company to Biofrontera Inc.

Incyte

3.20K
Botanix Pharmaceuticals logo - Similar company to Biofrontera Inc.

Botanix Pharmaceuticals

53
Galderma logo - Similar company to Biofrontera Inc.

Galderma

8.13K
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) logo - Similar company to Biofrontera Inc.

Arcutis Biotherapeut...

378
Biofrontera Group logo - Similar company to Biofrontera Inc.

Biofrontera Group

95
AbbVie logo - Similar company to Biofrontera Inc.

Abbvie

57.01K
Almirall logo - Similar company to Biofrontera Inc.

Almirall

2.33K

Top Biofrontera Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant